Výsledky vyhledávání - "Kimberley J. Campbell"

Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia

Autor: Stephen Chaplin, Bridgette Kanz Schroader, Kimberley J. Campbell, Gary H. Lyman, Edward C. Li, David Campbell

Publikováno v: Journal of Clinical Oncology. 39:58-58

58 Background: The introduction of biosimilar colony-stimulating factors has led to the reduction in prices for these historically expensive therapies. To understand the impact of recent pricing trends on delivering efficient care, the cost-effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be585ed131dad18580c2adb410fb7398
https://doi.org/10.1200/jco.2020.39.28_suppl.58

Zobrazit plný text záznamu

Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017

Autor: Edward C. Li, Anupama Vasudevan, Robert M. Rifkin, Lisa Herms, Kimberley J. Campbell, Chuck Wentworth

Publikováno v: Journal of Clinical Oncology. 39:57-57

57 Background: Biosimilars have potential to reduce healthcare costs and increase access in the United States, but lack of uptake has contributed to lost savings. Filgrastim-sndz was the first FDA-approved biosimilar, and much can be learned by evalu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b909daaad40ba3952fd6c344ac2cc144
https://doi.org/10.1200/jco.2020.39.28_suppl.57

Zobrazit plný text záznamu

Association of febrile neutropenia (FN) risk factors (RFs) with incident FN in U.S. commercial and Medicare advantage patients receiving intermediate-risk chemotherapy for non-myeloid cancers between 2009 and 2019

Autor: Kimberley J. Campbell, Gary H. Lyman, Lincy S. Lal, Jesse Peterson-Brandt, Edward C. Li, Elizabeth J. Bell

Publikováno v: Journal of Clinical Oncology. 39:e18607-e18607

e18607 Background: FN after myelosuppressive chemotherapy may result in significant morbidity/mortality and increase healthcare costs due to interventions such as hospitalization. For patients receiving chemotherapy at intermediate-risk of FN, guidel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::433b2a64b2b95646cc0553388a3317db
https://doi.org/10.1200/jco.2021.39.15_suppl.e18607

Zobrazit plný text záznamu

Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk

Autor: Dylan Mezzio, Gary H. Lyman, Edward C. Li, Andrew Spargo, Kimberley J. Campbell

Publikováno v: Journal of Clinical Oncology. 38:73-73

73 Background: According to clinical practice guidelines, the threshold for routine myeloid growth factor (MGF) PP is a high risk (>20%) of developing FN. However, in response to the COVID-19 pandemic, a recent recommendation expands this threshold f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2c3f702175abdfe41e23f546ba437ad
https://doi.org/10.1200/jco.2020.38.29_suppl.73

Zobrazit plný text záznamu

Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk

Autor: Dylan Mezzio, Andrew Spargo, Edward C. Li, Kimberley J. Campbell, Gary H. Lyman

Publikováno v: Journal of Clinical Oncology. 38:e19401-e19401

e19401 Background: Patients with nonmetastatic NSCLC receiving platinum-based chemotherapy are at an intermediate risk (10-20%) of developing FN; clinical practice guidelines recommend assessing whether these patients have FN risk factors before cons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c158702eef07fe8aec58b61bf3cc3986
https://doi.org/10.1200/jco.2020.38.15_suppl.e19401

Zobrazit plný text záznamu

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

Autor: Kelly Richardson, Daniel D. Von Hoff, Evan M. Hersh, Neil Desai, David W. Nyman, Vuong Trieu, Kimberley J. Campbell, Michael J. Hawkins, Kristen Long

Publikováno v: Journal of Clinical Oncology. 23:7785-7793

Purpose ABI-007 is a novel solvent-free, albumin-bound, 130-nm particle formulation of paclitaxel designed to avoid solvent-related toxicities and to deliver paclitaxel to tumors via molecular pathways involving an endothelial cell-surface albumin re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c741b7684a850221bf11aef643b843
https://doi.org/10.1200/jco.2004.00.6148

Zobrazit plný text záznamu

A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies

Autor: D. D. Von Hoff, David W. Nyman, Vuong Trieu, Kelly Richardson, Evan M. Hersh, K. Patrick, Kimberley J. Campbell, Neil P. Desai

Publikováno v: Journal of Clinical Oncology. 22:2027-2027

2027 Background: To evaluate the safety/tolerability, maximum tolerated dose (MTD), and anti-tumor effect of nanoparticle paclitaxel (ABI-007). This novel Cremophor-free formulation was administere...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5458d89ce12bd6966b3a2e6bdc147569
https://doi.org/10.1200/jco.2004.22.90140.2027

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání